PT-141

FDA Approved

Bremelanotide

Category
Sexual Health
Aliases
Bremelanotide, Vyleesi
Administration
Subcutaneous injection (approved), Intranasal (research)

Documented side effects

Tier 1 · Peer-reviewed / regulatory

Nausea (~40% of users)

One of the most common side effects, reported in a substantial share of users in clinical trials.

Flushing

A temporary warm, reddened sensation in the skin, typically resolving on its own.

Hyperpigmentation with repeated use

Skin may darken gradually with continued use, related to this compound's activity on melanocortin receptors.